Show simple item record

dc.contributor.advisorAlferraly, T. Ibnu
dc.contributor.advisorDelyuzar
dc.contributor.authorSusanto, Febri
dc.date.accessioned2025-07-23T05:56:14Z
dc.date.available2025-07-23T05:56:14Z
dc.date.issued2022
dc.identifier.urihttps://repositori.usu.ac.id/handle/123456789/106340
dc.description.abstractMalignant melanoma is a potentially aggressive and lethal malignancy deriving from melanocytic cells. Although it comprises only 3% of all cutaneous malignancies diagnosed each year, malignant melanoma contributes to 75% of all skin cancer deaths. In the last decades, there have been advances in immune checkpoint inhibitor (ICPI) development in treating melanoma metastases. ICPI such as programmed cell death ligand-1 (PD L1) is primary membrane-bound protein expressed in dendritic cells and monocytes. Programmed cell death protein- 1 (PD-1) inhibitors or PD-L1 inhibitors will clinically improve treatment response and overall survival rates in many types of tumors. Nowadays, PD-L1 is being intensively used in cancer patient management revolution, especially in melanoma and non small cell lung cancer. Therefore, the researchers were interested in assessing the relationship between PD-L1 immunohistochemical expression and clinicopathology of malignant melanoma patients in General Hospital Haji Adam Malik Medan. Objective: To analyse the relationship between PD-L1 immunohistochemical expression and clinicopathology characteristics of malignant melanoma in General Hospital Haji Adam Malik Medan. Materials and Methods: A cross-sectional analytic study was performed using formalin-fixed tissue paraffin blocks from 18 skin cancer patients histopathologically diagnosed as malignant melanoma. Clinical data of patients (age, gender, tumor location) was acquired from medical record. Each slide was double blindly reevaluated by researcher and two pathologist. Tumor depth, tumor invasion and histopathological subtypes was evaluated. After that, each slide was stained with PD-L1 immunohistochemistry. Then, the relationship between PD-L1 immunohistochemical expression and clinicopathology characteristics of malignant melanoma was assessed and analyzed with statistical software by using the chi-square or Fisher’s exact test. Results and Discussion: In this study found that there are statistically significant relationship between the expression of PD-L1 with Breslow and tumor location in malignant melanoma (p value 0.045 and 0.013, respectively). Gadiot et al also discovered that there is significant correlation between PD-L1 expression with Breslow. Massi et al. stated that PD-L1 is a prognostic marker in melanoma. Based on multivariat analyses, found that Breslow-thickness is an independent risk factors for melanoma-specific death. High PD-L1 expression is often correlated with prognosis of malignant melanoma, and this prognosis is related with stage.en_US
dc.language.isoiden_US
dc.publisherUniversitas Sumatera Utaraen_US
dc.subjectmalignant melanomaen_US
dc.subjectPD-L1en_US
dc.subjectPD-1en_US
dc.subjectcutaneousen_US
dc.titleHubungan Ekspresi Imunohistokimia Programmed Cell Death Ligand-1 (PD-L1) pada Melanoma Malignan dengan Karakteristik Klinikopatologi di RSUP Haji Adam Malik Medanen_US
dc.title.alternativeAn Immunohistochemical Study of the Relationship Between Programmed Cell Death Ligand-1 (PDL-1) and Clinicopathological Characteristics of Malignant Melanoma in General Hospital Haji Adam Malik Medanen_US
dc.typeThesisen_US
dc.identifier.nimNIM167108008
dc.identifier.nidnNIDN0012026205
dc.identifier.nidnNIDN0019026301
dc.identifier.kodeprodiKODEPRODI11754#Patologi Anatomik
dc.description.pages62 Pagesen_US
dc.description.typeKarya Tulis Profesien_US
dc.subject.sdgsSDGs 4. Quality Educationen_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record